Reuters: Regulatory News: Rigel to drop skin disease drug after trial failure

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

The Best Way to Manage your Money. Start using Mint today to set a budget, track your goals and do more with your money. From our sponsors

Rigel to drop skin disease drug after trial failure Oct 24th 2013, 11:55 Thu Oct 24, 2013 7:55am EDT Oct 24 (Reuters) - Rigel Pharmaceuticals Inc said it would stop the development of its drug to treat skin lesions in patients with discoid lupus, a chronic skin disease, after the treatment failed a mid-stage study. The company said the drug, codenamed R333, did not meet the main goal of reducing the redness and roughness of flaky skin in patients with the disease, which is characterized by sores that can lead to scarring and hair loss. Rigel also said it met with the U.S. Food and Drug Administration for its blood disorder drug, fostamatimib, and will start two late-stage studies of the drug in the first half of 2014. Rigel shares were halted in premarket trading.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions